Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00414466 · ClinicalTrials.gov registry record · Phase 2

A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain

A Phase 2 study, sponsored by MedtronicNeuro.

Terminated
Registry status
Phase 2
Development phase
254
Enrollment target

NCT00414466: Clinical Trial Phase 2 study, sponsored by MedtronicNeuro.

NCT00414466 is a Phase 2 study that was terminated before completion, run by MedtronicNeuro. The registered enrollment target is 254 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00414466, a Phase 2 study, was terminated before completion, sponsored by MedtronicNeuro.

TERMINATED
Registry status
Phase 2
Development phase
254 participants
Enrollment target

Study Summary

The purpose of this study is to determine the safety and minimum effective dose of intraspinal gabapentin when delivered through an implanted drug infusion system.

Primary Outcome

Average pain score calculated over last 7 days of baseline minus average pain score calculated over last 7 days of follow-up using the Numeric Pain Rating Scale where 0=no pain, 10=worst possible pain.

Interventions

  • DRUG Intraspinal Gabapentin

Trial Details

FieldValue
Enrollment Target 254 participants
Start Date 2006-12
Est. Completion 2010-08
Phase Phase 2
MedtronicNeuro

51 total trials

Why NCT00414466 stopped before completion

NCT00414466 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% higher).

The record links to 0 conditions, and to 1 intervention - of which Intraspinal Gabapentin is the first listed.

NCT00414466 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00414466 about?

NCT00414466 is a clinical study titled "A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain". The purpose of this study is to determine the safety and minimum effective dose of intraspinal gabapentin when delivered through an implanted drug infusion system.

What is the current status of trial NCT00414466?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2006-12. Estimated completion is 2010-08.

What interventions are being tested in trial NCT00414466?

The interventions under investigation include: Intraspinal Gabapentin (DRUG).

Who is sponsoring clinical trial NCT00414466?

This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00414466's enrollment target sits among peer trials

254 219th of 2000 higher than 1,781 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04390737 · 254 participants · Phase 1

    Evaluate the Safety and Clinical Activity of HH2853

  • NCT04677647 · 254 participants · NA

    OurChild: A Health IT Solution to Reduce Minority Health Disparities

  • NCT05503797 · 254 participants · Phase 2

    A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • NCT06167317 · 254 participants · Phase 1

    Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00414466, the US trial registry maintained by the National Library of Medicine. NCT00414466 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.